Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Weighted Average) (2016 - 2025)

Sunshine Biopharma's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 492.39% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 492.39%, while the annual FY2025 figure was $4.2 million, 492.39% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $4.2 million in Q4 2025 per SBFM's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $15.6 million in Q2 2025 to a low of $11914.0 in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $4.0 million, with a median of $2.4 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 99.92% in 2023, then skyrocketed 37991.66% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then plummeted by 99.92% to $12825.0 in 2023, then surged by 5371.73% to $701749.0 in 2024, then surged by 492.39% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Shares Outstanding (Weighted Average) are $4.2 million (Q4 2025), $4.6 million (Q3 2025), and $15.6 million (Q2 2025).